The "White Paper on the Status Quo of the Behavior of Chinese Melanoma Patients" was officially launched

On May 15th, at the 2021 "Chinese Society of Clinical Oncology (CSCO) Melanoma Diagnosis and Treatment Guidelines" tour, the "Chinese Melanoma Patients" jointly sponsored by the CSCO Melanoma Expert Committee, the CSCO Patient Education Expert Committee, and the China Medical Tribune The “White Paper on Behavior Status Survey” project (hereinafter referred to as “White Paper on Chinese Melanoma Patients”) was officially launched.

Melanoma is known as the "king of cancer" and is a malignant tumor with high mortality, high metastasis rate and difficult treatment.

As the "leading tumor" in the field of tumors, melanoma has developed early and updated global research, and its academic philosophy has always been at the forefront of the entire anti-tumor treatment.

The road to diagnosis and treatment of melanoma with Chinese characteristics urgently needs Chinese data

As the vice chairman of the International Melanoma Association, Professor Guo Jun has always been committed to promoting the development of melanoma diagnosis and treatment with Chinese characteristics.

In recent years, the breakthroughs made in Chinese melanoma research have exerted extensive influence in the international melanoma academic community.

Love is endless, adding further help to China's melanoma diagnosis and treatment business

In order to gain a deeper understanding of the current status of diagnosis and treatment of melanoma patients in my country, and make every effort to promote the diagnosis and treatment management and disease education of melanoma patients in China, the "White Paper on the Status Quo of Behaviors of Chinese Melanoma Patients" was officially launched.

references

[1] Chinese melanoma diagnosis and treatment guidelines (2013 edition).